SCHEMBL5475170

SCHEMBL5475170

Cc1cc(C=C2SC(=O)N(Cc3ccc(Cl)c(Cl)c3)C2=O)cc(C(=O)Nc2ccc(O)c(O)c2)c1O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PPARG P37231 4/20 0.47
▸ PTPN1 P18031 3/20 0.44
▸ ACP1 P24666 3/20 0.44
▸ MEN1 O00255 6/20 0.43
▸ KMT2A Q03164 6/20 0.43
▸ ALDH1A1 P00352 4/20 0.43
▸ MAPT P10636 4/20 0.43
▸ L3MBTL1 Q9Y468 4/20 0.43
▸ TDP1 Q9NUW8 3/20 0.43
▸ ENPP2 Q13822 2/20 0.43
▸ KDM4E B2RXH2 2/20 0.43
▸ MCL1 Q07820 2/20 0.43
▸ DUSP3 P51452 2/20 0.43
▸ MAPK1 P28482 2/20 0.43
▸ DNMT1 P26358 1/20 0.43
▸ POLB P06746 3/20 0.43
▸ LMNA P02545 2/20 0.43
▸ BLM P54132 2/20 0.43
▸ SAE1 Q9UBE0 2/20 0.43
▸ UBA2 Q9UBT2 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5475169 1.00 PPARG (0.47) PPARGPTPN1ACP1MEN1KMT2A
SCHEMBL5462662 0.90 MEN1 (0.55) PPARGPTPN1ACP1MEN1KMT2A
SCHEMBL5462658 0.90 MEN1 (0.55) PPARGPTPN1ACP1MEN1KMT2A
SCHEMBL5461461 0.89 MAPT (0.50) PPARGPTPN1ACP1MEN1KMT2A
SCHEMBL5461457 0.89 MAPT (0.50) PPARGPTPN1ACP1MEN1KMT2A
SCHEMBL5461202 0.84 PTPN1 (0.53) PPARGPTPN1ACP1MEN1KMT2A
SCHEMBL5461197 0.84 PTPN1 (0.53) PPARGPTPN1ACP1MEN1KMT2A
SCHEMBL5468711 0.83 ENPP2 (0.54) PPARGPTPN1ACP1MEN1KMT2A
SCHEMBL5468714 0.83 ENPP2 (0.54) PPARGPTPN1ACP1MEN1KMT2A
SCHEMBL5459300 0.81 PTPN1 (0.56) PTPN1ACP1MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070276011-A1 Plasminogen Activator Inhibitor-1 Inhibitor INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2007-11-29 — — US disclosed
EP-1666469-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR Institute of Medicinal Molecular Design, Inc. (JP) 2006-06-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070276011-A1 Plasminogen Activator Inhibitor-1 Inhibitor SERPINE1, SERPINC1, SERPINB1 PPARG 1078/4885PTPN1 3264/4885ACP1 254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback